The definition of non-responder to multiple sclerosis treatment: Neuroimaging markers

Neurological Sciences

Volumn 29, Issue SUPPL. 2, 2008, Pages

  Rovaris, Marco ^a  

^a IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

MRI; Multiple sclerosis; Treatment response

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE; PLACEBO;

ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; DIAGNOSTIC VALUE; DISABILITY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PROGNOSIS; RELAPSE; REMISSION; RISK REDUCTION;

BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 53649103143     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-008-0943-0     Document Type: Article

References (10)

1. Beck RW, Chandler DL, Cole SR et al (2002) Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 51:481-490
2. Polman C, Kappos L, Freedman MS et al (2008) Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b. J Neurol 255:480-487
3. Sormani MP, Bruzzi P, Comi G, Filippi M (2005) The distribution of the MRI response to glatiramer acetate in MS. Mult Scler 11:447-449
4. Sormani MP, Bruzzi P, Beckmann K et al (2005) The distribution of magnetic resonance imaging response to interferon b-1b in multiple sclerosis. J Neurol 252:1455-1458
5. Stone LA, Frank JA, Albert PS et al (1997) Characterization of MRI response to treatment with interferon beta-1b: Contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 49:862-869
6. Rudick RA, Lee JC, Simon J et al (2004) Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 56:548-555
7. Tomassini V, Paolillo A, Russo PL et al (2006) Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 253:287-293
8. Pozzilli C, Prosperini L, Sbardella E et al (2005) Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience. Neurol Sci 26[Suppl 4]:S174-S178
9. Stürzebecher S, Wandinger KP, Rosenwald A et al (2003) Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 126:1419-1429
10. Rovaris M, Agosta F, Sormani MP et al (2003) Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: A medium-term follow-up study. Brain 126:2323-2332